罕见病药物氨己烯酸片在国内上市了吗

Have rare disease drugs been launched in China? At present, vigabatrin tablets (vigabatrin) have not been launched in the country.

On August 21, 2009, the US FDA approved vigabatrin tablets (vigabatrin) as monotherapy for pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy.

On January 16, 2019, the FDA approved the launch of a generic version of generic vigabatrin tablets. Vigabatrin tablets (vigabatrin) are sold under the brand name Sabril in Canada, Mexico, and the United Kingdom. The Danish brand name is Sabrilex.

It is understood that vigabatrin tablets are only available in a few countries. The vigabatrin tablets (vigabatrin) produced by Sanofi in France are cost-effective. Its specifications are 500 mg

Taking vigabatrin for treatment may affect your ability to drive and use machinery. Generally, patients with uncontrolled epilepsy are not allowed to drive or operate potentially dangerous machinery. In view of reports of drowsiness during clinical use of vigabatrin, patients should be warned before initiating treatment with this drug.

(Vigabatrin) is an oral medicine that can be taken once or twice a day, before or after meals. It is advisable to drink half a glass of water when taking this medicine. Vigabatrin should be used under the guidance of an epilepsy specialist or child neurologist. Reactions after taking the medication should be reported to the doctor promptly.

Recommended related hot articles: /newsDetail/82926.html